IT HAS previously been demonstrated that the monoamine oxidase inhibitor, RO 4-1038 (DL-serine-N2-isopropylhydrazide) is a clinically useful drug in the treatment of arterial hypertension." 2 Furthermore, all the compounds that inhibit monoamine oxidase in vivo are hypotensive in man to a greater or lesser degree.3 Although the precise manner in which the disturbances of catecholamine metabolism produced by these agents result in hypotension is speculative,4 present methodology is adequate to determine their major hemodynamic effects. RO 4-1038 would appear to be an appropriate drug to study for this purpose, since it results in a greater hypotensive response than most of the other monoamine oxidase inhibitors ,' 2 and it is an analogue of iproniazid ( fig. 1 ) and thus has the typical configuration of most of the monoamine oxidase inhibitors.
Methods and Materials
Eleven male patients with consistent diastolic hvpertension of varying etiology were studied. an unequivocal decrease in blood pressure, and (2) RO a.
-J R 1000. Figure 4 Changes in calculated total peripheral resistance in supine and standing positions.
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right heart pressures17 and the reversal of hexamethonium hypotension by external counterpressure during immersion in water18 suggest a large component of venular dilatation. The ganglion-blocking agents cause a reduction in renal blood flow and glomerular filtration rate when given acutely; the renal hemodynamics tend to increase to pretreatment levels, however, with long-term use.'7
The early hypotensive action of the thiazides is considered to result from redueed cardiac output secondary to a contracted plasma volume1,9-25 although there are conflicting data and opinions.9 26 Blood pressure response to norepinephrine infusion before and after therapy with RO 4-1038. hexamethonium in that they cause a reduction in cardiac output without significant changes in peripheral resistance,33 34 and the orthostatic reduction in blood pressure can be overcome by counterpressure over the lower extrenmities with a "g-suit. "35 December 1962 sion.4 39 That the hypotensive effect of these compounds is not due to their hydrazide structure is indicated by the recent clinical studies with a nonhydrazine monoamine oxidase inhibitor. 44 Until more is known of the intermediary metabolism of the vasoactive amines as well as the changes caused by monoamine oxidase inhibition, these questions must remain unanswered.
Summary
Hemodynamic studies were performed on 11 patients with severe diastolic hypertension before and after the chronic administration of the monoamine oxidase inhibitor, RO 4-1038.
Although postural hypotension was more marked, the blood pressure decreased significantly in the supine position as well. The hypotensive effect was attributable alhnost solely to decreased total peripheral resistance and was unrelated to changes in cardiac output, blood volume, or sodium space. Renal plasma flow and glomerular filtration rate were unchanged.
Evidence is presented which suggests that the decrease in blood pressure was not caused by adrenergic bilockade. If RO 4-1038 is a representative monoamine oxidase inhibitor then its hemodynamic action is unique among the clinically useful hypotensive drugs.
Appendix
Since the control values in the supine position differed from the control values in the standing position, it was necessary to express the changes in each parameter after drug therapy as per cent change from control value in each position. In computation of the statistical results, therefore, a log transformation device was employed. For example, in comparing the mean blood pressure change following drug administration in the supine position with the change in the standing position, the natural logarithm for each observation was derived and the nmean and standard deviation were then calculated for the following two series:
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